FREGA, STEFANO
 Distribuzione geografica
Continente #
NA - Nord America 1.195
EU - Europa 165
AS - Asia 101
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.462
Nazione #
US - Stati Uniti d'America 1.194
IT - Italia 68
CN - Cina 62
SE - Svezia 29
FI - Finlandia 27
GB - Regno Unito 19
DE - Germania 14
VN - Vietnam 14
SG - Singapore 10
IN - India 9
TW - Taiwan 4
TR - Turchia 2
UA - Ucraina 2
CA - Canada 1
CH - Svizzera 1
ES - Italia 1
EU - Europa 1
FR - Francia 1
IE - Irlanda 1
NL - Olanda 1
RU - Federazione Russa 1
Totale 1.462
Città #
Fairfield 204
Woodbridge 134
Chandler 125
Ashburn 119
Cambridge 92
Houston 79
Seattle 73
Wilmington 70
Ann Arbor 38
Padova 27
San Diego 25
Beijing 24
Helsinki 22
Medford 18
Princeton 18
New York 17
Dong Ket 14
Des Moines 12
Roxbury 11
Columbus 8
Ogden 8
Nanjing 7
Pune 6
Washington 6
Boardman 4
Dearborn 4
Hsinchu County 4
Milan 4
Tianjin 4
London 3
Ningbo 3
Rome 3
Treviso 3
Avezzano 2
Belluno 2
Castagnole 2
Duncan 2
Grisignano di Zocco 2
Jinan 2
Los Angeles 2
Milazzo 2
Pignone 2
Portland 2
Sarego 2
Singapore 2
Acton 1
Amsterdam 1
Ankara 1
Bellaterra 1
Dublin 1
Guangzhou 1
Gunzenhausen 1
Haikou 1
Hangzhou 1
Hounslow 1
Jolanda di Savoia 1
Kilburn 1
Lappeenranta 1
Leawood 1
Norwalk 1
Nutley 1
Orange 1
Palermo 1
Redmond 1
Santa Clara 1
Shanghai 1
Taizhou 1
Toronto 1
Zonguldak 1
Totale 1.237
Nome #
A triple rare E709K and L833V/H835L EGFR mutation responsive to an irreversible pan-HER inhibitor: A case report of lung adenocarcinoma treated with afatinib 151
166P: Non-small cell lung cancer (NSCLC) patients with rare or complex epidermal growth factor receptor (EGFR) mutations: A single institution series 143
From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study) 131
Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations 118
Non-Small Cell Lung Cancer in a Very Young Woman: A Case Report and Critical Review of the Literature 117
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome 87
18F-FDG PET/CT in non-small-cell lung cancer patients: a potential predictive biomarker of response to immunotherapy 81
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non–small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy 77
Squamous cell carcinomas of the lung and of the head and neck: New insights on molecular characterization 72
Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future? 67
Clinical features and progression pattern of T790M+ compared with T790M-EGFR mutant NSCLC 65
1398P Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first- or second-generation tyrosine kinase inhibitor (1-2 gen TKI) 63
149P First-line (1L) osimertinib in EGFR mutant (mut) advanced non-small cell lung cancer (aNSCLC) patients (pts): Progression (PD) pattern and safety in the real-world (RW) 61
Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines 57
119P The role of circulating markers in predicting immune-related adverse events (irAEs) and their recurrence in advanced non-small cell lung cancer (aNSCLC) patients (pts) 56
How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center 52
Detection of loss of heterozygosity in cfDNA of advanced EGFR-or KRAS-mutated non-small-cell lung cancer patients 48
Plasma next-generation sequencing (NGS) in advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with immune checkpoint inhibitors (ICIs): Impact of STK11 and TP53 mutations on outcome 47
Totale 1.493
Categoria #
all - tutte 6.014
article - articoli 6.014
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.028


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201928 0 0 0 0 0 0 0 0 0 0 0 28
2019/2020291 21 13 4 78 29 18 18 28 32 18 28 4
2020/2021210 14 9 18 4 6 17 33 16 30 15 10 38
2021/2022371 17 45 40 16 26 43 49 21 13 10 30 61
2022/2023245 39 39 7 32 26 20 2 16 39 8 16 1
2023/2024218 15 17 32 21 25 61 14 9 12 5 7 0
Totale 1.493